Peptides for Focus and Memory: Reading the Nootropic Claims

Nobody goes looking for a nootropic peptide on a good day. People find Semax, Selank and dihexa when work has become harder to hold in their head, when words go missing mid-sentence, or when they have read that someone sharper is using them. That context matters, because the marketing is written for exactly that feeling.

Cognitive enhancement is where peptide marketing makes its boldest leaps. The claims borrow language from neuroscience — BDNF, neuroplasticity, synaptogenesis — that sounds precise, and they describe results mostly from rodents, cell cultures and studies outside the US regulatory system. This guide goes through the main compounds one at a time, says what is actually known, and explains what a sensible workup for "I can't think straight" looks like.

Why "nootropic peptide" is a hard claim to prove

Before the compounds, a note on why this category is especially slippery.

Cognition is difficult to measure well. Short-term tests can move with practice, caffeine, sleep and motivation. Many people who start a nootropic also start sleeping better, drinking less, and paying closer attention to their work, and all of those help. Expectation effects on subjective focus are strong. That is why the standard for a cognitive claim should be a randomized, blinded, placebo-controlled trial with a validated outcome measure — and why "I felt sharper" reviews tell you almost nothing.

There is also a mismatch in populations. Peptides are sold to healthy professionals chasing an edge, but most of the human research, where it exists, involves stroke, brain injury or diagnosed disease. A result in recovery after stroke does not tell you what happens in a healthy 38-year-old brain.

Semax

Semax is a synthetic seven-amino-acid peptide based on a fragment of adrenocorticotropic hormone (ACTH), modified to last longer. It was developed in Russia, where it is a registered prescription medicine and appears on the national list of vital and essential drugs. It is usually given as nasal drops.

In Russia it has been used in stroke and other neurological conditions. Much of the published clinical work is in Russian-language journals, often small, and not always designed or reported to the standards FDA would require. Animal studies describe effects on BDNF and on dopamine and serotonin systems. What does not exist, as far as we can find, is a body of large, independent, placebo-controlled trials showing that Semax improves cognition in healthy adults.

Semax was one of the substances FDA's Pharmacy Compounding Advisory Committee voted on in July 2026. The committee narrowly recommended it for the 503A bulk substances list, against the conclusion of FDA's own reviewers that none of the nominated substances met the criteria. That vote is advisory. Before Semax could lawfully be compounded from bulk substance, FDA would need to complete notice-and-comment rulemaking, and no final rule had been reported as of this writing. See the July 2026 vote, explained.

Selank

Selank is a synthetic analogue of tuftsin, a small immune-related peptide, also developed and registered in Russia and also typically given intranasally. It has been positioned mainly as an anti-anxiety medicine, with claims about focus following on from that.

Its clinical evidence has the same shape as Semax's: small studies, largely published in Russian. One frequently cited 2008 Russian study compared Selank with a benzodiazepine in people with generalized anxiety and neurasthenia, rather than with placebo. Head-to-head designs like that can be informative, but they do not tell you whether either drug beats a sugar pill, and they are not studies of cognition in healthy people.

When worry or low mood is what is eroding your concentration, that is worth raising directly with a clinician, because well-studied options exist. Neither Semax nor Selank is FDA-approved. Selank's compounding status has been in flux, and a clinician should be able to tell you exactly where each stands today.

Dihexa

Dihexa is the compound where the gap between marketing and evidence is widest. It is a small modified peptide derived from angiotensin IV, developed at Washington State University as a potential Alzheimer's treatment. Rat studies published around 2013 reported that it increased connections between nerve cells in culture and improved performance in a spatial memory task in cognitively impaired rats.

A 2021 evidence summary from the Alzheimer's Drug Discovery Foundation's Cognitive Vitality program found no published human studies. It also flagged a specific concern: dihexa is thought to act through the hepatocyte growth factor (HGF)/c-Met pathway, a signaling system that is also a key driver in many cancers. Nobody has tested whether long-term use carries that risk, because nobody has tested long-term use in humans at all.

Dihexa is among the substances expected to come before FDA's compounding advisory committee in a further review in February 2027. It is not FDA-approved.

Cerebrolysin

Cerebrolysin is not a single peptide but a mixture of peptides and amino acids derived from pig brain tissue. It is approved in a number of countries outside the US for conditions such as stroke and dementia, is given by injection or infusion, and is sometimes promoted in wellness settings for "brain optimization".

Stroke is where it has been tested most rigorously. A 2023 Cochrane systematic review (Ziganshina and colleagues) pooled seven randomized trials with 1,773 participants in acute ischemic stroke. The authors concluded, with moderate certainty, that Cerebrolysin and similar peptide mixtures probably have no beneficial effect on preventing death, and they found an increase in non-fatal serious adverse events among people who received it. It is not FDA-approved.

That is a useful reality check. A peptide product that has been through several randomized trials in people did not show the benefit its mechanism suggested on the outcome that matters most — and still showed a harm signal.

Athletes and tested professionals

None of Semax, Selank, dihexa or Cerebrolysin is named on the World Anti-Doping Agency's 2026 Prohibited List. That is not the same as being permitted. WADA's S0 category prohibits, at all times, any pharmacological substance not covered elsewhere on the list that has no current approval by any government health authority for human therapeutic use. A compound with no approval anywhere, such as dihexa, may fall under that clause. Status can also change year to year.

Anyone who competes under USADA or WADA rules should check a specific substance with their anti-doping organization before using it. Our guide to peptides and drug testing goes further.

What actually causes brain fog, and what a good workup looks like

Here is the part the nootropic market skips. Trouble concentrating and remembering is a symptom with a long list of common, testable, treatable causes. A clinician worth seeing will look at these before discussing any peptide:

• Sleep. Short sleep, irregular schedules and untreated sleep apnea are among the most common drivers of poor focus. Snoring, waking unrefreshed and daytime sleepiness are clues. See peptides and sleep for why a peptide is rarely the answer there either.
• Thyroid function, iron and B12. Underactive thyroid, iron deficiency and low vitamin B12 can all blunt thinking and are simple blood tests.
• Blood sugar. Swings in glucose affect concentration, and diabetes is often undiagnosed.
• Hormones. Perimenopause commonly brings "brain fog"; low testosterone in men can affect energy and concentration. Our pieces on women over 40 and low testosterone symptoms cover both.
• Medications and alcohol. Antihistamines, some sleep aids, some pain medicines and regular drinking all affect cognition.
• Mood. Low mood and anxiety can both show up as poor concentration.
• Red flags. Rapidly worsening memory, getting lost in familiar places, personality change, new severe headaches or neurological symptoms need prompt in-person medical evaluation, not a supplement.

Where a peptide conversation fits

We talk with people about cognitive peptides regularly. The honest version of that conversation usually goes like this: we look for the common causes first, order the tests that make sense for you, and explain plainly where each compound stands legally and scientifically. Sometimes that turns up something fixable. Sometimes it confirms that nothing obvious is wrong, and the most useful plan is about sleep, alcohol, exercise and workload rather than a vial.

What we won't do is promise a prescription, or treat an unapproved compound with rat data as though it were a proven cognitive enhancer. If you want that kind of assessment, you can read about our peptide therapy consultations, see what happens in a consultation, or book a consultation directly.

For a closer look at the two Russian compounds specifically, including their history and route of administration, read Semax and Selank, examined.

Common questions

What is the best peptide for focus and memory?

There isn't one with good evidence in healthy people. No peptide is FDA-approved for cognitive enhancement, and the most-marketed options rely on animal studies or small Russian trials. The best-supported improvements usually come from fixing sleep, treating deficiencies and addressing medications or mood.

Is Semax legal in the US?

Semax is not FDA-approved. An FDA advisory committee narrowly recommended it for the 503A bulks list in July 2026, but that vote is non-binding and FDA must complete rulemaking before pharmacies could lawfully compound it from bulk. As of this writing that had not happened. Rules change; verify current status with FDA or your clinician.

Has dihexa been tested in humans?

We are not aware of any published human studies. The evidence comes from rat and cell work, and there are unanswered questions about long-term safety given the growth pathway it acts on.

Do nasal peptides reach the brain?

The nose offers a possible route toward the brain for some molecules, which is why Semax and Selank are given that way. How much of a particular product reaches brain tissue in humans, and whether that produces a benefit, is not well established. Our article on oral, nasal and injectable peptides explains the trade-offs.